The patent winter is coming
Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?
Another strike for biotech: China
Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.
How China applicants could avoid the sintilimab scenario
A US adcom savages sintilimab, but the biggest problems identified might be sintilimab-specific.
